Toxins (Basel). 2026 Apr 8;18(4):179. doi: 10.3390/toxins18040179.
ABSTRACT
Hyperphosphatemia is a major complication in patients with kidney failure undergoing dialysis and is strongly associated with cardiovascular disease, vascular calcification, and increased mortality. Conventional management relies on dietary phosphate restriction, oral phosphate binders, and dialysis, yet persistent hyperphosphatemia affects a substantial proportion of patients. High-volume hemodiafiltration, combining diffusive and convective clearances, achieves greater phosphate removal than standard hemodialysis, with kinetic modeling predicting ~15-20% higher dialytic phosphate clearance (and ~0.5 mg/dL lower predialysis serum phosphate when nondialytic factors are constant). In this narrative review, we quantify the magnitude of improvement in dialytic clearance of phosphate with hemodiafiltration relative to hemodialysis and evaluate its effects on phosphate control measures. We also analyze phosphate balance in selected hemodiafiltration vs. hemodialysis comparisons and demonstrate why predialysis serum phosphate levels are sometimes only modestly lower or similar when hemodiafiltration is compared with hemodialysis. These findings are largely attributable to nondialytic factors-minor differences in phosphate binder equivalent dose, dietary phosphate ingestion, or residual kidney function-as predicted by phosphate kinetic modeling and supported by clinical trial data. Recognizing these confounders is essential for interpreting hemodiafiltration's phosphate-lowering potential in real-world practice.
PMID:42043043 | DOI:10.3390/toxins18040179